Articles tagged "Lung transplantation"

2017 American Transplant Congress
The Role of Anti-Neu5Gc IgM in Xenograft Antibody Mediated Rejection.
W. Hassanein,¹ G. Braileanu,¹ L. Burdorf,¹ W. Sun,¹ B. French,¹ C. Laird,¹ S. Sendil,¹ C. Ahn,³ D. Ayares,² R. Pierson III,¹ A. Azimzadeh.¹
¹University of Maryland School of Medcine, Baltimore, MD; ²Revivicor, Blacksburg, VA; ³Seoul National University Hospital, Seoul, Korea
Background:Acute antibody mediated rejection due to preformed antibodies present in human serum remains a hurdle to successful xenotransplantation. Here, we measured anti-Neu5Gc-IgM antibody titers in…
2017 American Transplant Congress
Immune Monitoring-Guided Treatment of a Pediatric Patient with Sequential GvHD, Acute Rejection and CMV Infection Following Lung Transplantation.
C. Falk,¹ S. Nicolaus,² M. Carsten,² T. Igor,³ S. Wiebke,³ D. Kerstin,¹ K. Jana,² H. Gesine,² H. Axel,³ W. Gregor.³
¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany; ²Department of Pediatric Pulmology, Hannover Medical School, Hannover, Deutschland, Germany; ³Department of Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Deutschland, Germany
Background: A 17 year old patient with cystic fibrosis (HLA-A11+, CMV-) underwent bilateral sequential lung transplantation (donor: HLA-A32+, CMV+). Immunosuppression (IS) consisted of Tacrolimus, MMF…
2017 American Transplant Congress
Impact of Caregiver on 30 Day Readmission After Lung Transplant.
T. Coco, C. Keller, F. Alvarez, D. Erasmus, J. Mallea.
Department of Transplantation, Mayo Clinic Florida, Jacksonville, FL
The type of primary caregiver has been associated with long-term outcomes after lung transplantation. There is no data on the impact of caregiver associated with…
2017 American Transplant Congress
Outcomes After Lung Transplant: Being a Teenager Does Not Stop at Age 18.
R. Baker,¹ R. Rizwan,¹ R. Bryant III,¹ M. Schecter,² C. Towe,² J. Tweddell,¹ F. Zafar,¹ D. Morales.¹
¹Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH; ²Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
Recipient age at lung transplantation impacts survival. Adolescent recipients grouped by legal age definition (12-18) have been shown across all types of solid organ transplantation…
2017 American Transplant Congress
Novel Biomarkers for Segregating Lung Transplant Rejection Phenotypes.
J. Yang,¹ B. Vanaudenaerde,² T. Sigdel,¹ J. Liberto,¹ S. Verlden,² M. Sarwal.¹
¹Department of Surgery, University of California, San Francisco, San Francisco, CA; ²Department of Pneumology, University of Leuven, Leuven, Flemish Brabant, Belgium
We sought to investigate biomarkers in BAL fluid and tissue for segregating BOS and RAS chronic rejection phenotypes in lung allografts. We had previously identified…
2017 American Transplant Congress
Characterization of a B Lymphocyte Signature Predictive of Chronic Lung Allograft Dysfunction.
C. Brosseau,^1,2 M. Durand,^1,2 E. Durand,^1,2 J. Loy,² A. Foureau,² P. Lacoste,² P.-J. Royer,² A. Magnan,² S. Brouard.¹
¹INSERM UMR1064, Centre de Recherche en Transplantation et, Nantes, France; ²INSERM UMR1087, Institut du Thorax, Nantes, France
The occurrence of chronic lung allograft dysfunction (CLAD) is the main complication after lung transplantation (LT) and remains the most common cause of graft failure…
2017 American Transplant Congress
Preoperative Pulmonary Hypertension Is Not Associated with Adverse Outcomes After Lung Transplantation.
S. Biswas Roy,¹ M. Olson,² D. Harned,¹ P. Kang,³ R. Panchanathan,³ A. Hashimi,¹ J. Huang,¹ H. Abdelrazek,¹ V. Patel,¹ A. Omar,¹ R. Bremner,¹ M. Smith,¹ R. Walia,¹ A. Kalya.⁴
¹Norton Thoracic Institute, Phoenix; ²Grand Canyon University, Phoenix; ³University of Arizona, Phoenix; ⁴St. Joseph's Hospital and Medical Center, Phoenix
Purpose: The effect of preoperative pulmonary hypertension (PH)[mdash]that is, mean pulmonary artery pressure (mPAP) of 25mmHg or higher[mdash]on lung transplantation (LTx) outcomes is debatable.Methods: We…
2017 American Transplant Congress
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome Appearance After Lung Transplantation.
R. Danger,¹ P. Royer,² D. Reboulleau,² J. Loy,² A. Tissot,² P. Lacoste,² A. Roux,³ M. Reynaud-Gaubert,⁴ R. Kessler,⁵ S. Mussot,⁶ C. Dromer,⁷ O. Brugière,⁸ J. Mornex,⁹ R. Guillemain,¹⁰ M. Dahan,¹¹ C. Knoop,¹² K. Botturi,² C. Pison,¹³ L. Nicod,¹⁴ S. Brouard,¹ A. Magnan,² COLT and SysCLAD Consortia.
¹CRTI UMR1064, INSERM, Université de Nantes, ITUN, CHU Nantes, Nantes, France; ²UMR_S 1087 CNRS UMR_6291, Institut du Thorax, Université de Nantes, CHU de Nantes, Nantes, France; ³CHU de Marseille, Aix Marseille Université, Marseille, France; ⁴CHU de Strasbourg, Strasbourg, France; ⁵Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardiopulmonaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France; ⁶CHU de Bordeaux, Bordeaux, France; ⁷Service de Pneumologie et Transplantation Pulmonaire, Hôpital Bichat, Paris, France; ⁸Université de Lyon, INRA, UMR754, Lyon, Hospices Civils de Lyon, Lyon, France; ⁹Hôpital Européen George Pompidou, Paris, France; ¹⁰CHU de Toulouse, Toulouse, France; ¹¹Hôpital Erasme, Bruxelles, Belgium; ¹²Clinique Universitaire Pneumologie, Pôle Thorax et Vaisseaux, CHU de Grenoble, Université de Grenoble, Inserm U1055, Grenoble, France; ¹³Service de Pneumologie, Centre de Transplantation, Lausanne, Switzerland
Bronchiolitis obliterans syndrome (BOS) is the main manifestation of chronic lung allograft dysfunction responsible for the poor long-term outcome after lung transplantation. While physiopathological mechanisms…
2017 American Transplant Congress
High Regulatory T Cells Rate Early After Lung Transplantation Is Associated with Bronchiolitis Obliterans Syndrome Development.
M. Durand,^1,2 P. Lacoste,^2,3 C. Brosseau,^1,3 E. Durand,³ J. Loy,³ K. Henrio,^2,3 R. Danger,¹ P. Royer,³ A. Fourreau,³ A. Magnan,^3,4 S. Brouard.¹
¹INSERM U 1064, Center for Research in Transplantation and Immunology (CRTI), Nantes, France; ²Université de Nantes, Nantes, France; ³UMR INSERM 1087 CNRS 6291, Institut du Thorax, Nantes, France; ⁴Service de Pneumologie, Institut du Thorax, Nantes, France
Despite treatment improvement, the bronchiolitis obliterans syndrome (BOS) affects more than 50% of the lung-transplant recipient in the 5 years post-transplantation and because it cannot…
2017 American Transplant Congress
Eliminating False Positive Virtual Crossmatch Results for Lung Transplant Candidates by Using Multiple Antibody Testing Platforms.
O. Timofeeva,¹ M. Kashem,² S. Geier,¹ D. Grogan,² S. Keshavamurthy,² J. Gomez-Abraham,² Y. Toyoda,² F. Cordova.²
¹Department of Pathology and Laboratory of Medicine, Temple University, Lewis Katz School of Medicine, Philadelphia, PA; ²Department of Cardiovascular Surgery, Temple University, Lewis Katz School of Medicine, Philadelphia, PA
Purpose: At present, immunologic risk for lung transplant patients is evaluated based on Virtual crossmatch (VXM) by comparing recipient's HLA antibodies detected by Single antigen…